AI-Powered Drug
Discovery & Development
Accelerating pharmaceutical innovation by combining human expertise with AI and machine learning—powered by our proprietary EvolverAI® 2.0 platform.
Transforming Drug Discovery Through Intelligence
At BioXcel LLC, we specialize in accelerating drug discovery and development by harnessing the power of artificial intelligence and machine learning through our proprietary EvolverAI® 2.0 platform.
Whether you're a emerging biotech seeking to identify your first target or a large biopharma optimizing a late-stage pipeline, our data-driven, science-first approach delivers speed, clarity, and strategic advantage at every stage of the drug development process.
IGALMI™ Success Story
FDA-approved for acute agitation; developed by BioXcel Therapeutics (NASDAQ: BTAI)
Our Core Offerings
Revolutionary human and AI integrated solutions tailored to accelerate pharmaceutical innovation
Early Innovation & Discovery
Turn scientific hypotheses into validated targets Or build a high-confidence foundation for preclinical research.
We leverage EvoheaAI 2.0 to support early-stage innovation by identifying novel, high-potential targets Our platform combines multi-omics, literature, and biomedical data to generate data-backed hypotheses and de-risk early discovery decisions.
Capabilities:
- Target identification & validation
- Pathway analysis & biomarker discovery
- Prediction of Target's role in disease
- Mechanistic insights/relevance - e.g., target liability
- Indication scouting for early-stage assets
Pipeline Analysis & Optimization
Prioritize the right assets and shape your development strategy.
We help R&D and business development teams maximize pipeline ROI by providing deep insights into asset potential, competitive positioning, and unmet clinical needs. Our customized analyses enable data-driven prioritization, reduce portfolio risk, and enhance decision-making.
Capabilities:
- Identification of licensing opportunities
- Analysing the existing and future opportunity
- Competitive Landscape- Analysis of existing and future drugs/companies/M&As in pipeline for the disease
- Clinical trial benchmarking
- Target Product Profile
- Addressable Patient pool and expected market size
- Sales forecast and NPV analysis
- Trial site identification
- KOL selection
- Indication Expansion to increase TAM
- Activity Tracking
- Across therapy areas, companies (deals, fundings etc.),
- Pipeline and product updates
- Trend analysis
- Identification of partner for commercialization
Licensing & Deal Support
Make smarter deals, faster—with scientific and commercial rigor.
Our team supports in-licensing and out-licensing activities by offering comprehensive technical and strategic assessments. Whether you're scouting external innovation or seeking partners for your own assets, we help articulate scientific value, identify opportunities, and facilitate due diligence.
Capabilities:
- Technical due diligence for in-licensing
- Value proposition development for out-licensing
- Asset benchmarking & partner identification
- Deal strategy & outreach support
Re-Innovation
Extend asset value through indication expansion and repositioning.
Our AI models enable creative and science-grounded rethinking of existing molecules. We specialize in discovering new therapeutic opportunities—including repositioning, label expansion, and 505(b)(2) pathways—to maximize return on R&D investments.
Capabilities:
- Indication expansion via disease-target mapping
- Drug repurposing using clinical and real-world data
- 505(b)(2) regulatory strategy support
- Lifecycle management planning
AI-Driven Drug Discovery Partnerships
Collaborate end-to-end—from target to concept.
We offer flexible, high-impact partnerships tailored to your innovation goals. From concept exploration to AI-powered compound discovery, BioXcel can serve as your discovery engine or as a force multiplier alongside your internal teams.
Engagement Models:
- Fully managed AI-driven discovery programs
- Joint development partnerships
- Target scouting and ranking
- Hit-to-lead acceleration using EvolverAI 2.0
Why choose BioXcel?
Discover what sets BioXcel apart as your trusted partner in AI-driven drug discovery and development. Our proven track record speaks for itself.
Proven Impact
350+ projects, including an FDA-approved drug
Deep Expertise
20+ years in AI-ML applied to life sciences
Custom Engagements
Tailored solutions for biotechs, mid-size pharma, and global majors
Accelerated Timelines
Rapid insights and data-backed decisions
Success Story: IGALMI®
-
1
Target Identification
AI-powered analysis identified the optimal molecular target
-
2
Compound Selection
Machine learning algorithms identified dexmedetomidine as most promising
-
3
Clinical Development
Optimized clinical trial design with AI-driven patient stratification
-
4
FDA Approval
Successfully approved for acute treatment of agitation
From AI discovery to patient benefit
Contact US
bd@bioxcel.com
+1 475 237 9007